ATE486055T1 - Neue verbindungen, ihre herstellung und verwendung - Google Patents
Neue verbindungen, ihre herstellung und verwendungInfo
- Publication number
- ATE486055T1 ATE486055T1 AT05747983T AT05747983T ATE486055T1 AT E486055 T1 ATE486055 T1 AT E486055T1 AT 05747983 T AT05747983 T AT 05747983T AT 05747983 T AT05747983 T AT 05747983T AT E486055 T1 ATE486055 T1 AT E486055T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- diabetes
- pharmaceutical compositions
- type
- production
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 108010015181 PPAR delta Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400719 | 2004-05-05 | ||
| PCT/EP2005/052014 WO2005105726A1 (en) | 2004-05-05 | 2005-05-03 | Novel compounds, their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE486055T1 true ATE486055T1 (de) | 2010-11-15 |
Family
ID=34968773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05747983T ATE486055T1 (de) | 2004-05-05 | 2005-05-03 | Neue verbindungen, ihre herstellung und verwendung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7968723B2 (de) |
| EP (1) | EP1745003B1 (de) |
| JP (1) | JP2007536343A (de) |
| AT (1) | ATE486055T1 (de) |
| DE (1) | DE602005024384D1 (de) |
| ES (1) | ES2352085T3 (de) |
| WO (1) | WO2005105726A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070026503A (ko) * | 2004-05-14 | 2007-03-08 | 아이알엠 엘엘씨 | Ｐｐａｒ 조절제로서의 화합물 및 조성물 |
| US7622491B2 (en) * | 2004-08-13 | 2009-11-24 | Metabolex Inc. | Modulators of PPAR and methods of their preparation |
| ES2372617T3 (es) * | 2005-06-30 | 2012-01-24 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de ppar-delta. |
| EP1999098A2 (de) * | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Verbindungen, die die ppar-aktivität modulieren, ihre herstellung und ihre verwendung |
| CN103298469A (zh) | 2010-08-31 | 2013-09-11 | 首尔大学校产学协力财团 | PPARδ激动剂的胎儿重编程的用途 |
| JP2012171911A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Ｐｐａｒ活性化剤 |
| CN112759515B (zh) * | 2020-12-28 | 2023-06-13 | 广东药科大学 | 一种新型FFA1和PPARα/γ/δ四重激动剂、其制备方法及其作为药物的用途 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4920132A (en) * | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US5324743A (en) * | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
| GB2279659B (en) * | 1993-07-05 | 1998-04-22 | Merck Patent Gmbh | Liquid crystalline material |
| ATE236137T1 (de) | 1996-02-02 | 2003-04-15 | Merck & Co Inc | Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| CA2245524A1 (en) | 1996-02-02 | 1997-08-07 | Wei Han | Antidiabetic agents |
| CA2244831A1 (en) | 1996-02-02 | 1997-08-07 | John T. Olson | Method of treating diabetes and related disease states |
| JP2002503202A (ja) | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | 抗糖尿病薬 |
| AU719663B2 (en) | 1996-12-23 | 2000-05-11 | Merck & Co., Inc. | Antidiabetic agents |
| AU8355998A (en) | 1997-07-24 | 1999-02-16 | Yamanouchi Pharmaceutical Co., Ltd. | Medicinal compositions with cholesterol-lowering effect |
| AU9696198A (en) | 1997-10-17 | 1999-05-10 | Aventis Pharmaceuticals Products Inc. | Therapeutic uses of quinoline derivatives |
| JP2003500432A (ja) * | 1999-06-01 | 2003-01-07 | ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター | ジフェニルエーテル誘導体を用いて脱毛症を処置する方法 |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| AU7995300A (en) | 1999-10-05 | 2001-05-10 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
| AU1303301A (en) | 1999-11-10 | 2001-06-06 | Takeda Chemical Industries Ltd. | Body weight gain inhibitors |
| IL148579A0 (en) | 1999-11-11 | 2002-09-12 | Lilly Co Eli | Oncolytic combinations for the treatment of cancer |
| US6569901B2 (en) * | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
| JP2003523336A (ja) | 2000-02-18 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質障害のためのアリールオキシ酢酸 |
| MXPA02007603A (es) | 2000-03-09 | 2003-02-24 | Aventis Pharma Gmbh | Usos terapeuticos de mediadores ppar. |
| US6448293B1 (en) * | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
| JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| JP4790969B2 (ja) | 2000-08-11 | 2011-10-12 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| US6630504B2 (en) * | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
| GB0024361D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| JPWO2002046154A1 (ja) | 2000-12-05 | 2004-04-08 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031103D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| ATE433964T1 (de) | 2000-12-28 | 2009-07-15 | Takeda Pharmaceutical | Alkansäurederivate, verfahren zu deren herstellung und deren verwendung |
| EP1357914A2 (de) | 2001-02-02 | 2003-11-05 | SmithKline Beecham Corporation | Verfahren zur behandlung von ppar vermittelten krankheiten |
| JP4157381B2 (ja) | 2001-03-23 | 2008-10-01 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体の活性化剤 |
| US7253178B2 (en) | 2001-03-28 | 2007-08-07 | Eisai Co., Ltd. | Carboxylic acids |
| WO2002080899A1 (fr) | 2001-03-30 | 2002-10-17 | Eisai Co., Ltd. | Agent de traitement de maladie digestive |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| WO2002098840A1 (en) | 2001-06-04 | 2002-12-12 | Eisai Co., Ltd. | Carboxylic acid derivative and medicine comprising salt or ester of the same |
| FR2826574B1 (fr) | 2001-06-29 | 2005-08-26 | Oreal | Compositions contenant un derive d'hydroxydiphenyl ether inhibant le developpement des odeurs corporelles |
| WO2003016291A1 (en) | 2001-08-10 | 2003-02-27 | Nippon Chemiphar Co., Ltd. | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ |
| US7371777B2 (en) | 2001-08-17 | 2008-05-13 | Eisai Co., Ltd. | Cyclic compound and PPAR agonist |
| IL160845A0 (en) | 2001-09-14 | 2004-08-31 | Tularik Inc | Linked biaryl compounds |
| MXPA04003398A (es) | 2001-10-12 | 2004-11-22 | Nippon Chemiphar Co | Activador para el receptor o activado con el proliferador de peroxisoma. |
| KR20050036876A (ko) | 2001-10-17 | 2005-04-20 | 노보 노르디스크 에이/에스 | 디카르복실산 유도체, 그것의 제제 및 치료에의 사용 |
| DE10151390A1 (de) | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| JP2003171275A (ja) | 2001-12-11 | 2003-06-17 | Sumitomo Pharmaceut Co Ltd | ＰＰＡＲδアゴニスト |
| WO2003072100A1 (en) | 2002-02-25 | 2003-09-04 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| JP4383177B2 (ja) | 2002-03-01 | 2009-12-16 | スミスクライン ビーチャム コーポレーション | ｈＰＰＡＲ活性化剤 |
| US20030207924A1 (en) | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
| US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| DE10222034A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Tetrahydroisochinolin-Derivate |
| GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| GB0214254D0 (en) | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| DE10229777A1 (de) | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
| JPWO2004007439A1 (ja) | 2002-07-10 | 2005-11-10 | 住友製薬株式会社 | ビアリール誘導体 |
| CA2499380A1 (en) | 2002-09-05 | 2004-03-18 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their therapeutical use |
| AU2003287912A1 (en) * | 2002-12-20 | 2004-07-14 | Novo Nordisk A/S | Dicarboxylic acid derivatives as ppar-agonists |
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| US20060241157A1 (en) | 2003-01-06 | 2006-10-26 | Conner Scott E | Heterocyclic ppar modulators |
| DE10300099A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Indol-Phenylsulfonamid-Derivate |
| AU2004210711B2 (en) * | 2003-02-12 | 2010-07-08 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| CN1751037A (zh) | 2003-02-14 | 2006-03-22 | 伊莱利利公司 | 作为ppar调节剂的磺酰胺衍生物 |
| JPWO2004080943A1 (ja) | 2003-03-11 | 2006-06-08 | 小野薬品工業株式会社 | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| EP1602642A4 (de) | 2003-03-13 | 2006-11-08 | Ono Pharmaceutical Co | Iminoetherderivatverbindungen und arzneimittel, die die verbindungen als wirkstoff enthalten |
| US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| CN1791409A (zh) | 2003-04-17 | 2006-06-21 | 凯利普西斯公司 | 作为 p p a r调节剂的 ( 3 －{ 3'－ [ ( 2 , 4 －双 －三氟甲基 －苄基)－ ( 5 －乙基 －嘧啶 － 2 －基 )－氨基 ]－丙氧基} －苯基) －乙酸及相关化合物以及治疗代谢失调的方法 |
| US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| WO2004099170A2 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
| WO2005054176A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| AU2005230838A1 (en) | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as PPAR delta |
| CN100516065C (zh) | 2004-04-01 | 2009-07-22 | 安万特药物公司 | 1,3,4-二唑-2-酮作为PPAR-δ调节剂 |
| AU2005231358A1 (en) | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | Use of PPR delta agonists for treating demyelinating diseases |
| KR20070026503A (ko) | 2004-05-14 | 2007-03-08 | 아이알엠 엘엘씨 | Ｐｐａｒ 조절제로서의 화합물 및 조성물 |
| ES2372617T3 (es) | 2005-06-30 | 2012-01-24 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de ppar-delta. |
| EP1999098A2 (de) | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Verbindungen, die die ppar-aktivität modulieren, ihre herstellung und ihre verwendung |
-
2005
- 2005-05-03 ES ES05747983T patent/ES2352085T3/es not_active Expired - Lifetime
- 2005-05-03 US US11/579,712 patent/US7968723B2/en not_active Expired - Fee Related
- 2005-05-03 EP EP05747983A patent/EP1745003B1/de not_active Expired - Lifetime
- 2005-05-03 JP JP2007512189A patent/JP2007536343A/ja not_active Withdrawn
- 2005-05-03 DE DE602005024384T patent/DE602005024384D1/de not_active Expired - Lifetime
- 2005-05-03 AT AT05747983T patent/ATE486055T1/de not_active IP Right Cessation
- 2005-05-03 WO PCT/EP2005/052014 patent/WO2005105726A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1745003B1 (de) | 2010-10-27 |
| DE602005024384D1 (de) | 2010-12-09 |
| US20090209588A1 (en) | 2009-08-20 |
| US7968723B2 (en) | 2011-06-28 |
| WO2005105726A1 (en) | 2005-11-10 |
| JP2007536343A (ja) | 2007-12-13 |
| EP1745003A1 (de) | 2007-01-24 |
| ES2352085T3 (es) | 2011-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008024390A3 (en) | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders | |
| CY1112398T1 (el) | Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1 | |
| ATE528300T1 (de) | Bizyklische verbindungen und ihre verwendung als antidiabetika | |
| WO2006127503A3 (en) | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | |
| EA200870470A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
| CY1114660T1 (el) | ΠΑΡΑΓΩΓΑ 2-ΑΔΑΜΑΝΤΥΛΟΥΡΙΑΣ ΩΣ ΕΚΛΕΚΤΙΚΟΙ ΑΝΑΣΤΟΛΕΙΣ 11β-HSD1 | |
| EA200900940A1 (ru) | Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное | |
| ATE386715T1 (de) | Modulatoren des peroxisomproliferatoraktivierten rezeptors | |
| EA201200968A1 (ru) | Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин | |
| ATE555081T1 (de) | Adamantyl-derivate als inhibitoren des 11-beta- hydroxysteroid-dehydrogenase-1-enzyms | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| EA201100007A1 (ru) | Производные хиноксалиндиона | |
| BR0213253A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento de condições mediadas por receptores nucleares e de diabetes tipo i, diabetes tipo ii, dislipidemia, sìndrome x (incluindo a sìndrome metabólica, i.e. tolerância prejudicada à glicose, resistência á insulina, hipertrigliceridemia e/ou ou obesidade), doenças cardiovasculares (incluindo aterosclerose) ou hipercolesteremia | |
| RU2010120808A (ru) | Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение | |
| ATE496622T1 (de) | Verwendung von thienopyridonderivaten als ampk- aktivatoren und pharmazeutische zusammensetzungen,die diese enthalten | |
| WO2007056771A3 (en) | Compounds for the treatment of metabolic disorders | |
| EA200601869A1 (ru) | Карбоновые кислоты | |
| ATE479433T1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
| MX383582B (es) | Sulfonamidas como agonistas de gpr40 y gpr120. | |
| EP1948161A4 (de) | Verfahren zur prävention und behandlung von ppar-vermittelten zuständen mit macelignan | |
| DE602005024384D1 (de) | Neue verbindungen, ihre herstellung und verwendung | |
| BR0314335A (pt) | Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade | |
| WO2004037776A3 (en) | Novel compounds and their use as prar-modulators | |
| BRPI0417469A (pt) | bifenil carboxamidas substituìdas com n-aril piperidina | |
| ATE515494T1 (de) | Neue verbindungen, deren herstellung und verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |